ENCell Co

ENCell Co Debt

The Debt of ENCell Co (456070.KQ) as of Oct 27, 2026 is 9.00 B KRW. In the previous year, Debt was 5.15 B KRW — a change of 74.78% (higher).

Debt

9.00 BKRW

YoY

74.78%

Last updated:

In 2025, ENCell Co's total debt was 9.00 B KRW, a 74.78% change from the 5.15 B KRW total debt recorded in the previous year.

The ENCell Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2021
22.60 B KRW
Jan 1, 2022
26.12 B KRW
Jan 1, 2023
4.42 B KRW
Jan 1, 2024
5.15 B KRW
Jan 1, 2025
9.00 B KRW
The ENCell Co Debt history
YEARDebtYoY
9.00 BKRW+74.78%
5.15 BKRW+16.61%
4.42 BKRW-83.09%
26.12 BKRW+15.56%
22.60 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ENCell Co Stock analysis

What does ENCell Co do? ENCell Co Ltd generates revenue through the development and research of cell and gene-based biopharmaceuticals, offering biopharmaceutical quality testing services, and providing biopharmaceutical consignment production. The company serves pharmaceutical and biotechnology firms requiring advanced drug development solutions and quality assurance. Its primary focus is on cell and gene therapies, with services tailored to support clients in the biopharmaceutical industry. The firm's offerings include research, testing, and production services for biopharmaceutical products. The company's core business model revolves around delivering specialized services to clients in the life sciences sector. It targets pharmaceutical companies and biotech firms seeking to develop and produce cell and gene-based treatments. ENCell's quality testing services ensure regulatory compliance and product safety, while its consignment production supports clients in scaling manufacturing without capital investment. These services collectively address key needs in the biopharmaceutical development lifecycle. ENCell Co Ltd's revenue streams are derived from research contracts, testing service fees, and consignment production agreements. The company's clients include pharmaceutical and biotechnology firms that outsource their biopharmaceutical development and production needs. By focusing on cell and gene-based therapies, ENCell positions itself as a specialized partner for clients navigating the complexities of modern biopharmaceutical innovation. ENCell Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding ENCell Co's Debt Structure

ENCell Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing ENCell Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to ENCell Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in ENCell Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about ENCell Co stock

Debt of ENCell Co is 9.00 B KRW in 2025.

Debt of ENCell Co changed from 5.15 B KRW to 9.00 B KRW, representing a 74.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt ENCell Co since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's ENCell Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — ENCell Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — ENCell Co